MetaCap

Elicio Therapeutics (ELTX) vs Intercure (INCR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Intercure (INCR) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 50.6% versus a loss of 82.8%. Over five years, INCR leads with a -90.9% price change compared with -96.1% for ELTX. Intercure is the larger company by market cap ($42.0 million vs $41.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELTX-82.84%INCR-50.57%
+84%-4%-91%
Nov 21, 20251 yearNov 20, 2026
ELTX-96.46%INCR-91.77%
+9%-46%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELTX versus INCR key metrics
MetricELTXINCR
Share price$1.45$3.24
Market cap$41.05M$42.03M
1-day change-3.33%-7.69%
YTD return-81.78%-28.79%
1-year return-82.84%-50.57%
5-year return-96.13%-90.87%
EPS (TTM)$-1.81$-0.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-39.57M—
52-week high$16.00$7.55
52-week low$1.25$3.12
Distance from 52-week high-90.94%-57.09%
Analyst consensusstrong_buy—
Avg. price target upside+842.76%—
Average volume324.71K15.93K
Shares outstanding28.31M12.97M
Employees33285
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INCR has outperformed ELTX by 32.3 percentage points over the past year.

About Elicio Therapeutics

ELTX stock →

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

About Intercure

INCR stock →

InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.

Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees

ELTX vs INCR FAQ

Which is bigger, Elicio Therapeutics or Intercure?

Intercure (INCR) is larger, with a market capitalization of $42.03M compared with $41.05M for Elicio Therapeutics (ELTX).

Which stock has performed better over the past year, ELTX or INCR?

INCR returned -50.57% over the past 12 months, compared with -82.84% for ELTX (price return, excluding dividends). Past performance does not predict future results.

Are Elicio Therapeutics and Intercure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons